FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc shared pre-clinical data, demonstrating the potentially disease-modifying effects of Lucid-MS —the company’s lead drug candidate for the potential treatment of multiple sclerosis (MS) in the animal models of MS.
The Toronto-based biotech company said that based on more than a decade of research, Lucid-MS is a patented neuroprotective new chemical entity that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions.
READ: FSD Pharma announces appointment of Dr Eleanor N. Fish to its Research and Clinical Advisory Board
In order to demonstrate the unique potential therapeutic value of this Lucid-MS, the company has released a video explaining its pre-clinical results, including visual evidence of functional recovery on pre-clinical subjects.
“Lucid-MS has demonstrated the potential to prevent the degradation and help re-establish myelin which is evidenced by the functional recovery of mice as well as immunohistochemistry in this study, and several other studies in preclinical animal models,” said Dr. Lakshmi P. Kotra, CEO of Lucid Psycheceuticals Inc, FSD Pharma (CSE:HUGE, NASDAQ:HUGE)’s wholly-owned subsidiary.
She added: “This effect holds good promise for further development as a potential treatment for MS, and the biochemical mechanism of Lucid-MS represents a potential industry first in treating MS. We are eager to advance Lucid-MS to the clinic as quickly as we can.”
The featured study uses an Experimental Autoimmune Encephalitis (EAE) mouse model, a commonly used immune-mediated mouse model of MS.
MS is typically characterized as an autoimmune disease. Ten days following immunization with the antigen, mice received 1 milligram of Lucid-MS or saline (placebo). Test subjects were monitored for 50 days and were continually assessed for clinical symptoms; those that received Lucid-MS demonstrated an improvement in clinical score, compared with subjects that received placebo.
FSD Pharma is also advancing the development of its other drug candidates, including Lucid-PSYCH, a psychoactive molecule targeted to treat major depressive disorder, and FSD-PEA, an anti-inflammatory compound.
The biotech company is working with three drug candidates in different stages of development. FSD BioSciences, Inc is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine.
Through the company’s wholly-owned subsidiary, Lucid, the company is also focused on the research and development of its lead compounds, Lucid-PSYCH and Lucid-MS.
Contact Ritika at ritika@proactiveinvestors.com